Depression and cognitive disorders remain major challenges in healthcare, with conventional treatments often facing limitations such as slow onset, side effects, and poor drug delivery to the brain.Biomimetic nanodelivery systems, including nanozymes, cell membrane-based valhalla axys systems, and exosomes, have emerged as promising solutions to these issues.These systems leverage natural biological processes to enhance drug targeting, improve bioavailability, and regulate complex biological pathways.
Nanoenzymes, with their catalytic properties, offer antioxidant and anti-inflammatory benefits, while cell membranes and exosomes provide efficient targeting and immune evasion.However, challenges remain, including the immaturity of large-scale production techniques, stability concerns, and incomplete understanding of their mechanisms of action.Moreover, the long-term safety, pharmacokinetics, and toxicity of these systems require further investigation.
Despite here these obstacles, the potential of biomimetic nanodelivery systems to revolutionize depression treatment is significant.Future research should focus on optimizing their preparation, improving drug targeting and release, and ensuring clinical safety.Multidisciplinary collaboration will be essential for advancing these systems from the laboratory to clinical practice, offering new therapeutic avenues for depression and other neurological disorders.